Lipophilicity in drug discovery

Bibliography

• Richet C. On the relationship between the toxicity and the physical properties of substances. Compt Rendus Seances Soc Biol 1893;9:775-776
   Google Scholar
• Overton CE. Studies of Narcosis. London: Chapman and Hall; 1990
   Google Scholar
• Overton CE. Studien über die Narkose zugleich ein Beitrag zur allgemeinen Pharmakologie. 1901
   Google Scholar
• Meyer H. Welche eigenschaft der anasthetica bedingt inre Narkotische wirkung? Arch Exp Pathol Pharmakol 1899;42:109-118
   Google Scholar
• Meyer H. Zur Theorie der Alkoholnarkose Archiv für Experimentelle Pathologie und Pharmakologie 1901;46:338-346
   Google Scholar
• Hansch C. Quantitative approach to biochemical structure-activity relationships Acc Chem Res 1969;2:232
   Web of Science ®Google Scholar
• Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 1997;23:3-25
   Web of Science ®Google Scholar
• Teague SJ, Davis AM, Leeson PD, Oprea T. The Design of Leadlike Combinatorial Libraries. Angew Chem (Int. Ed.) 1999;38:3743-8
   Google Scholar
• Leeson PD, Springthorpe B. The influence of drug-like concepts on decision-making in medicinal chemistry. Nat Rev Drug Discov 2007;6:881-90
   PubMed Web of Science ®Google Scholar
• Mannhold R, Ostermann, C, Poda GI, Tetko IV. Calculation of molecular lipophilicity: State-of-the-art and comparison of log P methods on more than 96,000 compounds. J Pharm Sci 2009;98:861-93
   PubMed Web of Science ®Google Scholar
• Available at: www.daylight.com
   Google Scholar
• The application of ADMET rules to compound design. SMi ADMET Conference 2009. London; 2009
   Google Scholar
• Tetko I, Poda G, Ostermann, C, Accurate in Silico log P predictions: One Can't Embrace the Unembraceable. QSAR & Combinatorial Science 2009;28:845
   Google Scholar
• Bruneau P, McElroy NR. logD7.4 modeling using Bayesian Regularized Neural Networks. Assessment and correction of the errors of prediction. J Chem Inf Model 2006;46:1379-87
   PubMed Web of Science ®Google Scholar
• Dearden JC. In silico prediction of aqueous solubility. Expert Opin Drug Discov 2006;1:31-52
   PubMed Web of Science ®Google Scholar
• Yalkowsky SH, Valvani SC. Solubility and partitioning I: solubility of non-electrolytes in water. J Pharm Sci 1980;69:912-22
   PubMed Web of Science ®Google Scholar
• Ran Y, Jain N, Yalkowsky SH. Prediction of aqueous solubility of organic compounds by the general solubility equation (GSE). J Chem Inf Comp Sci 2001;41:1208-17
   PubMedGoogle Scholar
• Curatolo W. Physical chemical properties of oral drug candidates in the discovery and exploratory drug development settings. Pharm Sci Technol Today 1998;19:387-93
   Google Scholar
• Kramer C, Heinisch T, Fligge T, A consistent dataset of kinetic solubilities for early-phase drug discovery. ChemMedChem 2009;4:1529-36
   PubMed Web of Science ®Google Scholar
• Kearns EH, Di L. Drug-like properties: concepts, structure design and methods: Elsevier; 2008
   Google Scholar
• Gleeson MP. Generation of a set of simple, interpretable ADMET rules of thumb. J Med Chem 2008;51:817-34
   PubMed Web of Science ®Google Scholar
• Yoshida F, Topliss JG. QSAR Model for Drug Human Oral Bioavailability. J Med Chem 2000;43:2575-85
   PubMed Web of Science ®Google Scholar
• Camenisch G, Alsenz J, van de Waterbeemd H, Folkers G. Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs' lipophilicity and molecular weight. Eur J Pharm Sci 1998;6:313-9
   Web of Science ®Google Scholar
• Camenisch G, Folkers G, van de Waterbeemd H. Shapes of membrane permeability-lipophilicity curves: Extension of theoretical models with an aqueous pore pathway. Eur J Pharm Sci 1998;6:321-9
   Web of Science ®Google Scholar
• Kakemi K, Arita T, Hori R, Konishi R. Absorption and excretion of drugs XXX. Absorption of barbituric acid derivatives from rat stomach. Chem Pharm Bull 1967;17:1534-9
   Google Scholar
• Lee AJ, King JR, Barrett DA. Percutaneous absorption: a multiple pathway model. J Control Release 1997;45:141-51
   Web of Science ®Google Scholar
• Garringues TM, Pérez-Varona AT, Climent E, Gastric absorption of acidic xenobiotics in the rat: Biophysical interpretation of an apparently atypical behaviour. Int J Pharm 1990;64:127-38
   Web of Science ®Google Scholar
• Wagner JG. Quantitaton of rate of gastrointestinal and buccal absorption of acidic and basic drugs based on extraction theory. J Pharmacokinet Biopharm 1973;1:23
   Google Scholar
• Wagner JG, Sedman AJ. J Pharmacokinet Biopharm 1973;1:23-50
   Google Scholar
• Ho NFH, Park JY, Morozowich W, Higuchi WI. In: Roche EB, Ed. Design of Bioparmaceutical Properties through Prodrugs and Analogs Washington, DC: APhA/APS; 1977. p 136-227
   Google Scholar
• Ho NFH, Park JY, Ni PF, Higuchi WI. In: Crouthamel WG, Sarapu A, Eds. Animal Models for Oral Drug Delivery in Man: In Situ and In Vivo Approaches Washington, DC: APhA/APS; 1983. p 27-106
   Google Scholar
• Adson A. Passive diffusion of weak organic electrolytes across Caco-2 cell monolayers: Uncoupling the contributions of hydrodynamic, transcellular, and paracellular barriers. J Pharm Sci 1995;84:1197
   PubMed Web of Science ®Google Scholar
• Kubinyi H. Quantitative structure activity relationships. IV. Non linear dependence of biological activity on hydrophobic character: a new model. Arzneim Forsch (Drug Res.) 1976;26:1991-7
   PubMed Web of Science ®Google Scholar
• Egan WJ. Prediction of drug absorption using multivariate statistics. J Med Chem 2000;43:3867-77
   PubMed Web of Science ®Google Scholar
• Waring MJ. Defining optimum lipophilicity and molecular weight ranges for drug candidates-Molecular weight dependent lower logD limits based on permeability. Bioorg Med Chem Lett 2009;19:2844-51
   PubMed Web of Science ®Google Scholar
• van de Waterbeemd H, Smith DA, Beaumont K, Walker DK. Property-based design: Optimization of drug absorption and pharmacokinetics. J Med Chem 2001;44:1313-33
   PubMed Web of Science ®Google Scholar
• Nassar AF, Kamel AM, Clarimont C. Improving the decision-making process in the structural modification of drug candidates: enhancing metabolic stability. Drug Discov Today 2004;9:1020-8
   PubMed Web of Science ®Google Scholar
• Lewis DFV, Dickins M. Baseline lipophilicity realtionships in human cytochromes P450 associated with drug metabolism. Drug Metab Rev 2003;35:1-18
   PubMed Web of Science ®Google Scholar
• Lewis DFV, Dickins M. Substrate SARs in human P450s. Drug Discov Today 2002;7:918-25
   PubMed Web of Science ®Google Scholar
• Johnson TW, Dress KR, Edwards M. Using the Golden Triangle to optimize clearance and oral absorption. Bioorg Med Chem Lett 2009;19:5560-4
   PubMed Web of Science ®Google Scholar
• Borchard U. Pharmacokinetics of beta-adrenoceptor blocking agents: Clinical sugnificance of hepatic and/or renal clearance. Clin Physiol Biochem 1990;8(suppl.2):28-34
   PubMedGoogle Scholar
• Varma MVS, Feng B, Obach RS, Physicochemical determinants of human renal clearance. J Med Chem 2009;52:4844-52
   PubMed Web of Science ®Google Scholar
• Obach RS, Lombardo F, Waters NJ. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug Metab Dispos 2008;36:1385-405
   PubMed Web of Science ®Google Scholar
• Davis AM, Webborn PJH, Salt DW. Robust assessment of statistical significance in the use of unbound/intrinsic pharmacokinetic parameters in quantitative structure-pharmacokinetic relationships with lipophilicity. Drug Metab Dispos 2000;28:103-6
   PubMed Web of Science ®Google Scholar
• Comer JEA. In: van de Waterbeemd H, Ed. Methods and principles in medicinal chemistry: Weinheim: Wiley VCH; 2003. p. 21-45
   Google Scholar
• Veber DF, Johnson SR, Cheng H, Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem 2002;45:2615-23
   PubMed Web of Science ®Google Scholar
• Martin YC. A bioavailability score J Med Chem 2005;48:3164-3170
   PubMed Web of Science ®Google Scholar
• Klippert P, Borm P, Noordhoek J. Prediction of intestinal first-pass effect of phenacetin in the rat from enzyme kinetic data - correlation with in vivo data using mucosal blood flow. Biochem Pharmacol 1982;31:2545-8
   PubMed Web of Science ®Google Scholar
• Oie S, Tozer TN. Effect of altered plasma protein binding on apparent volume of distribution. J Pharm Sci 1979;68:1203-5
   PubMed Web of Science ®Google Scholar
• Herve F, Urien S, Albengres E, Drug binding in plasma. A summary of recent trends in the study of drug and hormone binding. Clin Pharmacokinet 1994;26:44-58
   PubMed Web of Science ®Google Scholar
• Valko K, Nunhuk S, Bevan C, Fast gradient HPLC method to determine compounds binding to human serum albumin. Relationships with octanol/water and immobilized artificial membrane lipophilicity. J Pharm Sci 2003;92:2236-48
   PubMed Web of Science ®Google Scholar
• Lombardo F, Obach RS, Shalaeva MY, Feng G. Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data. J Med Chem 2002;45:2867-76
   PubMed Web of Science ®Google Scholar
• Lombardo F, Obach RS, Shalaeva MY, Feng G. Prediction of human volume of distribution values for neutral and basic drugs 2. Extended dataset and leave-class-out statistics. J Med Chem 2004;47:1242-50
   PubMed Web of Science ®Google Scholar
• Summerfield SG, Read K, Begley DJ, Central nervous system drug disposition: the relationship between in situ brain permeability and brain free fraction. J Pharmacol Exp Ther 2007;322:205-13
   PubMed Web of Science ®Google Scholar
• Liu X, Chen C. Strategies to optimise brain penetration in drug discovery. Current Opin Drug Discov and Dev 2005;8:505-12
   PubMed Web of Science ®Google Scholar
• Freire E. Do enthalpy and entropy distinguish first in class from best in class? Drug Discov Today 2008;13:869-74
   PubMed Web of Science ®Google Scholar
• Peters J-U, Schnider P, Mattei P, Kansy M. Pharmacological promiscuity: dependence on compound properties and target specificity in a set of recent Roche compounds. ChemMedChem 2009;4:680-6
   PubMed Web of Science ®Google Scholar
• Hughes JD, Blagg J, Price DA, Physiochemical drug properties associated with in vivo toxicological outcomes. Bioorg Med Chem Lett 2008;18:4872-5
   PubMed Web of Science ®Google Scholar
• Redfern W, Carlsson L, Davis A, Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 2003;58:32-45
   PubMed Web of Science ®Google Scholar
• Diller DJ. In silico hERG modeling: Challenges and progress. Current Computer-Aided Drug Design 2009;5:106-21
   Web of Science ®Google Scholar
• Waring MJ, Johnstone C. A quantitative assessment of hERG liability as a function of lipophilicity. Bioorg Med Chem Lett 2007;17:1759-64
   PubMed Web of Science ®Google Scholar
• Zachariae U, Giordanetto F, Leach AG. Side chain flexibilities in the human ether-a-go-go related gene potassium channel (hERG) together with matched-pair binding studies suggest a new binding mode for channel blockers. J Med Chem 2009;52:4266-76
   PubMed Web of Science ®Google Scholar
• Shamovsky I, Connolly S, David L, Overcoming undesirable hERG potency of chemokine receptor antagonists using baseline lipophilicity relationships. J Med Chem 2008;51:1162-78
   PubMed Web of Science ®Google Scholar
• Jamieson C, Moir EM, Rankovic Z, Wishart G. Medicinal chemistry of hERG optimizations: Highlights and hang-ups. J Med Chem 2006;49:5029-46
   PubMed Web of Science ®Google Scholar
• Ploemen JHTM, Kelder J, Hafmans T, Use of physicochemical calculation of pKa and clogP to predict phospholipidosis-inducing potential: A case study with structurally related piperazines. Experimental and Toxicologic Pathology 2004;55:347-55
   PubMed Web of Science ®Google Scholar
• Tomizawa K, Sugano K, Yamada H, Horii I. Physicochemical and cell-based approach for early screening of phospholipidosis-inducing potential. J Toxicol Sci 2006;31:315-24
   PubMedGoogle Scholar
• Vieth M, Sutherland JJ. Dependence of molecular properties on proteomic family for marketed oral drugs. J Med Chem 2006;49:3451-3
   PubMed Web of Science ®Google Scholar
• Paolini GV, Shapland RHB, van Hoorn WP, Global mapping of pharmacological space. Nature Biotechnology 2006;24:805-15
   PubMed Web of Science ®Google Scholar
• Ruben AJ, Kiso Y, Freire E. Overcoming roadblocks in lead optimisation: a thermodynoamic perspective. Chem Biol Drug Des 2006;67:2-4
   PubMed Web of Science ®Google Scholar
• Leeson PD, Davis AM. Time-related differences in the physical property profiles of oral drugs. J Med Chem 2004;47:6338-48
   PubMed Web of Science ®Google Scholar
• Wenlock MC, Austin RP, Barton P, A comparison of physiochemical property profiles of development and marketed oral drugs J Med Chem 2003;46:1250-1256
   PubMed Web of Science ®Google Scholar
• Schuster D, Laggner C, Langer T. Why drugs fail – a study on side effects in new chemical entities. Current Pharmaceutical Design 2005;11:3545-59
   PubMed Web of Science ®Google Scholar
• Hopkins AL, Groom CR, Alex, A. Drug Discov Today 2004;9:430-431
   PubMed Web of Science ®Google Scholar
• Morphy R. The influence of target family and functional activity on the physicochemical properties of pre-clinical compounds. J Med Chem 2006;49:2969-78
   PubMed Web of Science ®Google Scholar
• Ritchie TJ, Macdonald SJF. The impact of aromatic ring count on compound developability – are too many aromatic rings a liability in drug design? Drug Discov Today 2009;14:1011-20
   PubMed Web of Science ®Google Scholar
• Lovering F, Bikker J, Humblet C. Escape from flatland: Increasing saturation as an approach to improving clinical success. J Med Chem 2009;52:6752-6
   PubMed Web of Science ®Google Scholar